STAT July 2, 2024
Moderna has been awarded $176 million by the Biomedical Advanced Research and Development Authority to accelerate development of messenger RNA-based pandemic influenza vaccines, the company announced in a statement Tuesday.
BARDA, a strategic preparedness arm of the Department of Health and Human Services, has said for weeks that it has been in talks with mRNA vaccine manufacturers with an aim to diversify the government’s pandemic flu vaccine response capacity. The U.S. government already has vaccine contracts with and stockpiles of H5 vaccines made using other platforms by other manufacturers, including CSL Seqirus and Sanofi.
“mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the Covid-19 pandemic,”...
Today's Sponsors
Today's Sponsor